Table 5.
Liver and kidney functions in mice treated with the indicated compounds (control (PBS treatment)), (a) TP3 at 75 μg/mouse, TP4 at 25 μg/mouse; (b) TP3 at 150 μg/mouse, TP4 at 50 μg/mouse, tigecycline at 150 μg/mouse, imipenem at 150 μg/mouse, or ampicillin at 150 μg/mouse). The following parameters were measured in the blood: glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine (CRE), uric acid (UA), and total bilirubin (TBIL). Each bar represents the mean value from three determinations ±standard derivation (SD). Differences were defined as significant at p < 0.05. Different letters indicate a significant difference between two groups, while the same letter indicates no difference between two groups.
| (a) | ||||||
|---|---|---|---|---|---|---|
| Treatment | GOT (U/L) | GPT (U/L) | BUN (mg/dL) | CRE (mg/dL) | UA (mg/dL) | TBIL (mg/dL) |
| Control | 11.10 ± 4.60 | 6.10 ± 2.80 | 1.71 ± 0.09 | <0.10 | 0.47 ± 0.06 | 0.11 ± 0.05 |
| TP3 | 12.90 ± 5.90 (P > 0.05) | 7.80 ± 5.00 (P > 0.05) | 1.77 ± 0.10 (P > 0.05) | <0.10 | 0.55 ± 0.10 (P > 0.05) | 0.19 ± 0.05 (P > 0.05) |
| TP4 | 7.40 ± 2.20 (P > 0.05) | 5.80 ± 1.30 (P > 0.05) | 1.65 ± 0.08 (P > 0.05) | <0.10 | 0.52 ± 0.09 (P > 0.05) | 0.16 ± 0.05 (P > 0.05) |
| (b) | ||||||
| Treatment | GOT (U/L) | GPT (U/L) | BUN (mg/dL) | CRE (mg/dL) | UA (mg/dL) | TBIL (mg/dL) |
| Control | 8.67 ± 0.58 ab | 5.33 ± 0.58 ab | 1.67 ± 0.15 (P > 0.05) | <0.10 | 0.20 ± 0.1 a | 0.23 ± 0.06 c |
| TP3 | 10.60 ± 2.51 a | 6.60 ± 1.52 b | 1.73 ± 0.11 (P > 0.05) | <0.10 | 0.50 ± 0.10 c | 0.20 ± 0.00 bc |
| TP4 | 8.00 ± 2.00 ab | 6.30 ± 0.57 b | 1.90 ± 0.20 (P > 0.05) | <0.10 | 0.33 ± 0.05 abc | 0.13 ± 0.05 ab |
| TIG | 8.00 ± 1.73 b | 4.33 ± 0.57 a | 1.33 ± 1.09 (P > 0.05) | <0.10 | 0.43 ± 0.11 bc | 0.06 ± 0.00 a |
| IMP | 8.00 ± 1.00 ab | 5.30 ± 0.57 ab | 1.76 ± 0.15 (P > 0.05) | <0.10 | 0.26±0.11 ab | 0.10 ± 0.10 a |
| AMP | 8.00 ± 1.00 ab | 6.30 ± 0.57 b | 1.86 ± 0.05 (P > 0.05) | <0.10 | 0.20 ± 0.10 a | 0.10 ± 0.00 a |